Veracyte, Inc. (NASDAQ:VCYT) announced that data published today in theJournal of the National Cancer Institutedemonstrate that the company's Decipher Prostate Genomic Classifier may help identify African American men with early, localized prostate cancer who are most likely to harbor more aggressive disease. The data, from the prospective, multi-site VANDAAM Phase 2 clinical study, suggest that the genomic test may offer a robust improvement over clinical factors alone in risk-stratifying prostate cancer among African American men, which may help reduce disparities in prostate cancer outcomes.
"While African American men have both higher incidence and mortality associated...
ログインすると全部閲覧できます。
ログイン